Shockwave Medical

Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease, C2 catheters for treating coronary artery disease, and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

ShockWave Medical reports robust revenue growth and strategic expansion plans

ShockWave Medical's strong performance in Q4 and full year 2022 underscores its growth trajectory and market acceptance.
The company's strategic initiatives, including product approvals, acquisitions, and revenue outlook, position it for continued success in 2023.
While facing challenges in operational transitions and tax strategies, ShockWave Medical remains focused on leveraging opportunities for growth and market expansion.

Shockwave Medical reports stellar Q1 results and eyes global expansion

Shockwave Medical delivered robust Q1 2023 results, showcasing significant revenue growth and strong international performance.
The company's focus on market expansion, new product launches, and strategic acquisitions underpin its confidence in sustained growth.
While facing challenges such as staffing shortages and margin pressures, Shockwave Medical remains optimistic about its future prospects and market opportunities.
Continued investments in innovation, market expansion, and talent acquisition position the company well for future success and revenue growth.

Shockwave Medical reports robust Q2 earnings, eyes international growth

Shockwave Medical's strong financial performance in Q2 2023 reflects revenue growth, profitability, and operational efficiency.
Strategic investments, focus on market expansion, and upcoming product launches position the company for future success and revenue growth.
While facing challenges in product development and market uncertainties, Shockwave has opportunities for growth in international markets and product differentiation.

Shockwave Medical reports robust Q3 earnings and eyes global expansion

Shockwave Medical's strong Q3 performance, international growth, and promising product pipeline position the company for long-term success. Despite challenges in the U.S. peripheral business, the company remains confident in its evidence-backed interventions and overall growth potential. Strategic initiatives to address prior authorization issues and expand market presence underscore a proactive approach to sustaining growth.

Shockwave Medical reports record revenue and strategic growth initiatives

Shockwave Medical delivered strong financial performance in Q4 2023, with record revenue and profitability, driven by growth in key business segments and international markets.
The company's strategic focus on evidence-based market penetration, new product launches, and global expansion positions it for continued growth and market leadership.
Despite challenges in clinical evidence generation and reimbursement complexities, SWAV's proactive approach and financial strength offer resilience and growth opportunities.
SWAV's confidence in achieving milestones, expanding into new markets, and driving revenue growth through innovative products underscore a promising outlook for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shockwave Medical is developing the Lithoplasty™ family of balloon dilatation catheters that incorporate tiny lithotripsy electrodes designed to increase the compliance of rigid vascular and valvular lesions prior to low-pressure dilation, thereby limiting injury to healthy tissue and overcoming significant limitations of current revascularization technologies. The technology is built on traditional balloon catheter platforms rendering it inherently familiar and easy to use for cardiologists, interventional radiologists and vascular surgeons alike. In peripheral vessels, Lithoplasty™ could enable more effective angioplasty, less frequent bailout stent usage and enhanced lesion preparation prior to the use of drug eluting balloons (DEB) or bio-absorbable vascular scaffolds (BVS). In coronary vessels it could facilitate stent delivery and enhance vessel preparation prior to stent or BVS placement. Finally, in aortic valves the technology could vastly improve native tissue preparation prior to trans-catheter aortic valve replacement (TAVR) and valvuloplasty for those patients not suitable for TAVR.

Fastly

iRobot

Kura Sushi USA

PetIQ

Personalis Inc

Zuora

As we all know, nothing – including blue-chip bull markets – lasts forever. Given this reality, investors may want to spread out their exposure with small-cap stocks to watch.

9 Up-and-Coming Small-Cap Stocks to Watch

Despite doubling over a two-month period, this high-growth stock has given back most of its gains. What should investors think?

Is Shockwave Medical a Buy?

Abbott Labs

Intuitive Surgical

These medical device stocks should be poised for a happy new year.

3 Top Medical Device Stocks to Buy in January

Beyond Meat

Cortexyme Inc

IGM Biosciences Inc

Inmode Ltd

Karuna Therapeutics Inc

Nextcure

Palomar

Turning Point Therapeutics

Karuna Therapeutics, NextCure, and Cortexyme aren’t household names when it comes to investors looking at initial public offerings (IPOs), but they’ve been generating big-time returns for investors who didn’t buy into the hype of more familiar names like Uber or Lyft.

Non-Household Names Topped the List of IPO Winners in 2019

Zoom Video

Beyond Meat, Zoom Video, and ShockWave Medical have lost 35% to as much as 69% of their value since peaking earlier this year.

The Rise and Fall of 2019's Hottest IPOs

Nevro

These niche businesses are growing by leaps and bounds.

3 Under-the-Radar Healthcare Stocks to Buy in December

Autodesk

Amazon

Looking for stocks for the long term? You might want to consider buying shares of this e-commerce king, innovative medical device company, and design software leader.

3  Stocks  Poised for Huge Growth Over the Next Decade.

SANTA CLARA, Calif., Nov.  14, 2019  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced the pricing of its public offering of 2,481,781 shares of its common stock at a price to the public of $36.25 per share. All of the shares are being offered by Shockwave. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Shockwave, are expected to be approximately $90.0 million. The offering is scheduled to close on November 19, 2019, subject to the satisfaction of customary closing conditions. The underwriters for the offering also have a 30-day option to purchase up to an additional 372,267 shares of Shockwave’s common stock at the price to the public, less underwriting discounts and commissions. Shockwave’s common stock is listed on the Nasdaq Global Select Market under the ticker symbol “SWAV.”

Shockwave Announces - Pricing of Public Offering of Common Stock

SANTA CLARA, Calif., Nov.  12, 2019  (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. All of the shares of common stock are being offered by Shockwave. In addition, Shockwave intends to grant the underwriters a 30-day option to purchase up to an additional $11,250,000 of shares of its common stock. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Shockwave Announces Proposed - Public Offering of Common Stock

ShockWave Medical: Riding The Long And Bumpy Wave Ahead

ShockWave Medical, Inc. (SWAV) CEO Doug Godshall on Q3 2019 Results - Earnings Call Transcript

First Patient Enrolled in DISRUPT CAD IV Clinical Study for Treatment of Severely Calcified Coronary Arteries First Patient Enrolled in DISRUPT CAD IV Clinical Study for Treatment of Severely Calcified Coronary Arteries

Shockwave Initiates Study of Coronary Intravascular Lithotripsy in Japan

It's an amazing company with fantastic revenue growth. But there's one small problem that's keeping me on the sidelines.

Why Shockwave Medical Is Not a Buy

The medical device maker's stock has ridden a huge wave up and a big wave back down since the company's March IPO.

Why ShockWave Medical Stock Plunged 29% in September

Pinterest

Looking for IPO stocks to invest in? These fast-growing social media, video conferencing, and medical device companies are worth watching.

3 Recent (2019) IPOs to Add to Your Watch List

Fool.com contributor Brian Feroldi talks with Doug Godshall about the competitive landscape, growth drivers, long-term financial targets, and more.

Exclusive Interview: ShockWave's CEO Sits Down With The Motley Fool

TCT Presentation of DISRUPT CAD II EU Post-Market Study Confirms  Promissory DISRUPT CAD I Results

Shockwave Study Demonstrates Strong Safety and Procedural Success of Coronary IVL in Europe

Shares of the medical device maker nearly tripled in the first three months of trading before plummeting. Despite the wild swings, its long-term growth story appears intact.

Shockwave Medical Is Down 50%. Is It a Buy?

Though the company delivered positive news, so what could explain its stock price tumble?

Why ShockWave Medical Shares Are Tanking Today

Agency’s Breakthrough Device Designation Program Allows for Priority Review of Coronary Calcium Modification Technology Agency’s Breakthrough Device Designation Program Allows for Priority Review of Coronary Calcium Modification Technology

Shockwave Receives FDA Breakthrough Device Designation for the Coronary IVL System

ABIOMED

Vertex Pharmaceuticals

These healthcare winners have such strong competitive advantages that their theme song could be MC Hammer's "U Can't Touch This."

3 Healthcare Stocks That Have a Killer Advantage

Tandem Diabetes Care

Wayfair

The dog days of summer are finally behind us (on the calendar, anyway), but these three stocks offer sizzling growth potential.

3 Top Growth Stocks to Buy in the Final Month of Summer

The cardiovascular disease specialist continues to grow its top line at a breakneck speed.

ShockWave Medical Boosts Guidance After Another Strong Quarter

ShockWave Medical, Inc. (SWAV) CEO Doug Godshall on Q2 2019 Results - Earnings Call Transcript

Align Technology

DexCom

These medical device stocks appear to have what it takes to be long-term winners.

News for Shockwave Medical Stock (SWAV)